CC BY
23
KoHrpecu, cMMno3iyMM, WKonu / Congresses, Symposiums, Schools
degree of MVP showed that the probability of arrhythmic disorders they may have in 6.3 times higher than in patients with I degree of MVP (OR = 6.3). On this base we select the group of patients with high risk of arrhythmic complications of idiopathic MVP: young men with II— III degree of MVP and the presence of 4 or more musculoskeletal dysembriogenesis stigmas.
Conclusions. Thus, UCTD syndrome is a unique abnormal background for the existence of various clinical conditions with a wide range of symptoms. Early detection and correction of phenotypic markers of UCTD from the side of the musculoskeletal system will improve the quality of life of such patients and reduce possibility of disability in a future.
PANASIUK Y., KORDA M.
Ternopil State Medical University named after
I.Ya. Horbachevsky, Ternopil, Ukraine
Using of Lovastatin Nanoparticles for the Osteoporosis Treatment and Fracture Risk Reduction (Experimental Study)
Introduction. A new published experimental data and clinical studies demonstrate the ability of lovastatin to affect osteoregeneration. This effect of statins is realized through the increased expression of bone morphogene-tic protein 2. However, current studies on the possibility of statins to reduce the risk of fractures are controversial. The positive effect of statins on bone metabolism was observed with oral administration of these drugs but in very high doses. That is why it is so important to develop the new ways of statins delivering to fracture zones, particularly in the form of nanoparticles.
Aim. To investigate the possibility of using lovastatin in nanoparticles to restore posttraumatic bone defects in rats.
Materials and methods. White mature male rats (n = 168) were used in experiment. All animals were divided into four groups: I — intact animals, II — control group (animals with simulated bone defect), III — animals with bone defect, which were administered with lovastatin transdermally, IV — animals with bone defect treated with lovastatin incorporated into polymeric nanoparticles. The bone defect (2.0 mm in diameter) was
made by dental drill in the upper third of the tibia. The
III group of animals received lovastatin in doses 0.1, 1.0, 5.0 mg/kg during the whole period of experiment. The
IV group of rats was injected with lovastatin incorporated into polymeric nanoparticles directly into the fracture zones in a dose 1.0 mg/kg. The animals were decapitated on the 3rd, 7th, 14th and 28th day. Biochemical (activity of alkaline and acid phosphatases, mineralization index, collagenolytic activity of plasma, oxyproline Ca and P levels in plasma), radiographic, histological, and statistical methods were used in the study.
Results. Our results showed a positive effect of transdermal sdministration of lovastatin only in dose 5 mg/kg, which is significantly higher than the average therapeutic dose. There was no effect of transdermal applying of lovastatin in dose 0.1 and 1.0 mg/kg. At the same time the using of lovastatin incorporated into polymeric nanoparticles resulted in a significant decrease of the bone resorption symptoms on the 3rd and 7th day of the experiment, which was confirmed by the biochemical markers and histological examination. Using of incorporated into polymeric nanopar-ticles lovastatin also resulted in the strengthening of osteo-regeneration on the 14th day of experiment and resumption of posttraumatic bone defect on the 28th day.
Conclusion. In our studies we have shown that the incorporated into polymeric nanoparticles lovastatin induces posttraumatic osteoregeneration. The obtained results require further extensive research in this area.
PANKIV I.
Institute of Gerontology named after D.F. Chebotarev AMS Ukraine, Kyiv, Ukraine
Hypovitaminosis D in Autoimmune Thyroiditis Patients with Subclinical and Overt Hypothyroidism
Introduction. There is increasing interest in the role of vitamin D deficiency in a number of chronic health problems including autoimmune diseases. A number of factors have been implicated in pathogenesis of most autoimmune disorders, one of the most recent agents found to be associated with autoimmunity is vitamin 25(OH)D. Serum 25(OH)D, the most abundant circulating precursor of active vitamin D, is the most widely accepted indicator of vitamin D status and reflects combined contributions from cutaneous synthesis. Importantly, both vitamin D and thyroid hormone bind to similar receptors called steroid hormone receptors. A different gene in the
vitamin D receptor was shown to predispose people to autoimmune thyroid disease including Graves' disease and Hashimoto's thyroiditis.
Aim: to investigate the total vitamin 25(OH)D in 70 autoimmune thyroiditis patients with subclinical (n = 21) and overt (n = 49) hypothyroidism.
Material and methods. 70 patients and 20 apparently healthy individuals with matched age and sex were underwent a detailed clinical examination, thyroid function tests (TSH, fT4, fT3, thyroid peroxidase antibodies) and serum total vitamin 25(OH)D. They were living in Kolomyja region and recruiting to outpatient clinic of Central Regional Hospital during the period from September 2013 to July 2014. Written consent was taken from all participants in this study. They were classified into three main groups: Group I. Patients with autoimmune thyroiditis and subclinical hypothyroidism. It included 21 patients (3 male (14.3 %) and 18 female (85.7 %)), their mean ages 46.36 ± 2.84 years. They were
№ 2 (18), 2015
www.mif-ua.com
93
